Management of Heart Failure with Preserved Ejection Fraction (HFpEF)
Start SGLT2 inhibitors immediately in all symptomatic HFpEF patients—this is the only Class I recommendation with proven mortality and hospitalization benefit across the entire LVEF spectrum. 1, 2, 3
First-Line Pharmacologic Therapy
SGLT2 Inhibitors (Class I - Strongest Evidence)
Begin one of these agents at diagnosis:
- Dapagliflozin 10 mg daily (no titration needed) 1
- Empagliflozin 10 mg daily, may increase to 25 mg daily 1
These reduce HF hospitalizations by approximately 29% and show consistent benefit regardless of diabetes status, driven primarily by decreased hospitalizations rather than mortality reduction 4, 2. The DELIVER and EMPEROR-Preserved trials established this as foundational therapy 4, 5.
Critical perioperative consideration: Stop SGLT2i 3-4 days before scheduled surgery to prevent metabolic acidosis 6.
Diuretics for Congestion (Class I)
Loop diuretics are mandatory for symptomatic fluid overload:
- Furosemide: Start 20-40 mg daily, usual range 40-240 mg daily 7
- Bumetanide: Start 0.5-1.0 mg daily, usual range 1-5 mg daily 7
- Torsemide: Start 5-10 mg daily, usual range 10-20 mg daily 7
Titrate to the lowest dose that maintains euvolemia—excessive diuresis activates neurohormones and may worsen outcomes 8, 5. Monitor weight daily, renal function, and electrolytes closely. For refractory congestion, add metolazone 2.5-10 mg for sequential nephron blockade 5, 7.
Second-Tier Therapies (Class IIa-IIb)
Mineralocorticoid Receptor Antagonists
Consider particularly in patients with:
- LVEF on the lower end of the HFpEF spectrum (closer to 40-50%) 2, 3
- Poorly controlled hypertension 3
- Recent evidence from FINEARTS-HF trial 9
Dosing:
- Spironolactone: 12.5-25 mg daily, target 25-50 mg daily 1
- Finerenone: 10-20 mg daily, target 20 mg daily 1
Monitor potassium and creatinine closely—inappropriate use is potentially harmful 10.
Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Sacubitril-valsartan may be considered for:
- Patients with LVEF 45-57% (lower range of HFpEF spectrum) 2, 3
- Start 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily 1
PARAGON-HF showed benefit in lower LVEF subgroups within the HFpEF range 2, 3.
Angiotensin Receptor Blockers
Candesartan may decrease hospitalizations:
- Start 4-8 mg daily, target 32 mg daily 1
- CHARM-Preserved showed reduction in HF admissions 7
- Consider particularly for LVEF on lower end of spectrum 2, 3
Emerging Therapies
GLP-1 Receptor Agonists
For HFpEF patients with obesity (BMI ≥30):
- Semaglutide and tirzepatide improve quality of life and reduce HF events 11, 9, 12
- STEP-HFpEF (2023) and SUMMIT (2024) trials demonstrated benefit 9
- Particularly valuable given obesity's central role in HFpEF pathophysiology 11
Critical Comorbidity Management
Blood Pressure Control (Class I)
Target systolic BP <130 mmHg based on SPRINT trial evidence showing intensive control reduces HF events 3. Use SGLT2i, MRAs, or ARNi/ARBs as first-line agents to simultaneously treat HFpEF and hypertension.
Atrial Fibrillation Management (Class IIa)
Rate control is essential:
- Beta-blockers or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) for rate control 13
- Target resting heart rate <80 bpm and exercise heart rate in physiological range 13
- Rhythm control may improve symptoms in selected patients 3
- Anticoagulation per CHA₂DS₂-VASc score 13
Diabetes Management
Prioritize SGLT2i and GLP-1 agonists—these provide dual benefit for glycemic control and HF outcomes 11, 14. Avoid thiazolidinediones (potentially harmful) 10.
Coronary Artery Disease
Revascularization is reasonable when:
- Angina or demonstrable ischemia adversely affects HF symptoms 10
- Evaluate for viable myocardium before proceeding 7
Therapies to AVOID (Class III: Harm)
Do NOT use:
- Nitrates or phosphodiesterase-5 inhibitors routinely (ineffective for activity/QOL) 3
- Most calcium channel blockers except non-dihydropyridines for rate control 10
- NSAIDs (worsen fluid retention and renal function) 10
- Thiazolidinediones (cause fluid retention) 10
Acute Decompensation Management
For hospitalized patients with volume overload:
- Intravenous loop diuretics as continuous infusion or bolus dosing 15
- Add vasodilators (nitroglycerin, nitroprusside, nesiritide) if severely symptomatic without hypotension 15
- Transition to oral diuretics carefully before discharge, monitoring for hypotension and worsening renal function 15
- Continue GDMT (except SGLT2i) throughout hospitalization unless hemodynamically unstable 6
- Initiate SGLT2i before discharge if not already prescribed 2
Diagnostic Mimics to Exclude
Before confirming HFpEF, rule out:
- Cardiac amyloidosis: Check monoclonal protein screen, technetium pyrophosphate scan if LV wall thickness increased 16
- Hypertrophic cardiomyopathy: CMR if unexplained LV hypertrophy 16
- Valvular disease: Particularly mitral/tricuspid regurgitation, aortic stenosis 16
- Pericardial disease: Constrictive pericarditis can mimic HFpEF 16
- High-output states: Anemia, thyrotoxicosis, AV fistulas 16
Monitoring and Follow-Up
Essential monitoring parameters:
- Daily weights (report gain >2-3 lbs in 24 hours or >5 lbs in one week) 15
- Renal function and electrolytes (especially with diuretics and MRAs) 8, 7
- Blood pressure (supine and standing to detect orthostatic hypotension) 15
- Repeat echocardiography to assess trajectory and identify HF with improved EF 2, 3
If LVEF improves to >50%, continue all GDMT—the TRED-HF trial showed relapse occurs with withdrawal 4, 3.
Practical Treatment Algorithm
Step 1: Confirm diagnosis (exclude mimics), assess congestion Step 2: Start SGLT2i immediately + diuretics for congestion Step 3: Optimize blood pressure with MRA, ARNi, or ARB (especially if LVEF 40-50%) Step 4: Add GLP-1 agonist if obese (BMI ≥30) Step 5: Manage AF with rate control, anticoagulate appropriately Step 6: Address CAD, diabetes, CKD with evidence-based therapies Step 7: Monitor closely, adjust diuretics to maintain euvolemia at lowest effective dose
This stepwise approach prioritizes therapies with the strongest evidence for reducing hospitalizations and mortality while addressing the multifactorial pathophysiology of HFpEF 1, 2, 3, 11.